Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
ASCO 2022: Latest in prostate cancer, including PARP inhibitors
Dr Neal Shore, Prof Cora Sternberg, Prof Eleni Efstathiou and Prof Phil Cornford
ASCO 2022: Latest in prostate cancer, including PARP inhibitors ( Dr Neal Shore, Prof Cora Sternberg, Prof Eleni Efstathiou and Prof Phil Cornford )
6 Jun 2022
FOLFOXIRI plus panitumumab vs mFOLFOX6/PAN for unresectable RAS and BRAF wild-ty...
Dr Chiara Cremolini - University of Pisa, Pisa, Italy
FOLFOXIRI plus panitumumab vs mFOLFOX6/PAN for unresectable RAS and BRAF wild-type mCC ( Dr Chiara Cremolini - University of Pisa, Pisa, Italy )
6 Jun 2022
Dabrafenib plus trametinib significantly increases overall response rate in paed...
Dr Eric Bouffet - The Hospital for Sick Children, Toronto, Canada
Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas ( Dr Eric Bouffet - The Hospital for Sick Children, Toronto, Canada )
6 Jun 2022
Comment: Dabrafenib plus trametinib significantly increases overall response rat...
Dr Melissa Hudson- St. Jude Children's Research Hospital, Memphis, USA
Comment: Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas ( Dr Melissa Hudson- St. Jude Children's Research Hospital, Memphis, USA )
6 Jun 2022
ASCO 2022: Latest developments in mHSPC and mCRPC
Prof Heather Payne, Prof Kim Chi, Prof Laura-Maria Krabbe and Prof Kurt Miller
ASCO 2022: Latest developments in mHSPC and mCRPC ( Prof Heather Payne, Prof Kim Chi, Prof Laura-Maria Krabbe and Prof Kurt Miller )
6 Jun 2022
Safety follow-up of the randomized, phase 3 study DESTINY-Breast03
Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA
Safety follow-up of the randomized, phase 3 study DESTINY-Breast03 ( Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA )
5 Jun 2022
ASCO 2022: Latest in EGFR positive NSCLC
Prof Benjamin Besse, Dr Anna Minchom, Dr Antonio Passaro and Dr Enriqueta Felip
ASCO 2022: Latest in EGFR positive NSCLC ( Prof Benjamin Besse, Dr Anna Minchom, Dr Antonio Passaro and Dr Enriqueta Felip )
5 Jun 2022
COMy 2022: Multiple myeloma roundup
Prof Philippe Moreau - University Hospital of Nantes, Nantes, France
COMy 2022: Multiple myeloma roundup ( Prof Philippe Moreau - University Hospital of Nantes, Nantes, France )
24 May 2022
Long-term outcomes with sotorasib in pretreated KRASp.G12C-mutated NSCLC: 2-year...
Dr Grace Dy - Roswell Park Comprehensive Cancer Center, Buffalo, USA
Long-term outcomes with sotorasib in pretreated KRASp.G12C-mutated NSCLC: 2-year analysis of CodeBreaK100 ( Dr Grace Dy - Roswell Park Comprehensive Cancer Center, Buffalo, USA )
10 May 2022
War in Ukraine: Impacts on the Ukrainian cancer care system
Dr Andriy Hrynkiv - Lviv Regional Cancer Centre of Ukraine, Lviv, Ukraine
War in Ukraine: Impacts on the Ukrainian cancer care system ( Dr Andriy Hrynkiv - Lviv Regional Cancer Centre of Ukraine, Lviv, Ukraine )
4 May 2022
War in Ukraine: Impacts on the Polish cancer care system and vaccination challen...
Prof Piotr Rutkowski - National Research Institute of Oncology, Warsaw, Poland
War in Ukraine: Impacts on the Polish cancer care system and vaccination challenges ( Prof Piotr Rutkowski - National Research Institute of Oncology, Warsaw, Poland )
4 May 2022
Advance Prostate Cancer Consensus Conference 2021: Report
Prof Silke Gillessen and Prof Aurelius Omlin
Advance Prostate Cancer Consensus Conference 2021: Report ( Prof Silke Gillessen and Prof Aurelius Omlin )
29 Apr 2022